NCT04613700 (THE-ROSE) is a NA clinical trial of Secretin in Obesity, sponsored by Steno Diabetes Center Copenhagen.

Who is sponsoring NCT04613700?

NCT04613700 is sponsored by Steno Diabetes Center Copenhagen.

What drugs are being tested in NCT04613700?

Interventions in NCT04613700: Secretin, Placebo.

What condition does NCT04613700 study?

NCT04613700 studies Obesity, Metabolic Disease, Diabetes, Adiposity.

Is NCT04613700 still recruiting?

NCT04613700 is currently completed. Last updated 5 November 2020.

Last reviewed 2020-11-05 · How we verify

NCT04613700: THE-ROSE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Role of Secretin on the Energy Homeostasis

Completed NA Last updated 5 November 2020

What this trial tests

NA trial testing Secretin in Obesity in 25 participants. Completed in 29 September 2020.

Timeline

1 March 2020

Primary endpoint
29 September 2020

29 September 2020

Quick facts

Lead sponsor	Steno Diabetes Center Copenhagen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	basic science
Enrollment	25
Start date	1 March 2020
Primary completion	29 September 2020
Estimated completion	29 September 2020
Sites	1 location across Denmark

Drugs / interventions tested

Secretin — full drug profile →
Placebo

Conditions studied

Obesity — all drugs for Obesity →
Metabolic Disease — all drugs for Metabolic Disease →
Diabetes — all drugs for Diabetes →
Adiposity — all drugs for Adiposity →

Sponsor

Steno Diabetes Center Copenhagen — full company profile →

Who can join

Adults 18 to 75, male only, with Obesity or Metabolic Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

As of last year, new insight into the function of secretin was brought about as rodent studies showed secretin to possess potential body weight-regulating effects. In these studies, secretin was shown to increase non-shivering thermogenesis in brown adipose tissue (BAT), decrease meal size and promote meal discontinuation. The mechanisms behind these regulatory effect of secretin on energy homeostasis are unclear,

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

57<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes.
· 2021 · cited 11× · PMID 34468792 · DOI 10.1007/s00125-021-05519-y
Secretin infusion decreases food intake in healthy men-a randomized, placebo-controlled, double-blind, crossover study.
Heimbürger SMN, Bentzen MJ, Kizilkaya HS, Hartmann B, et al · · 2024 · cited 1× · PMID 39556772 · DOI 10.1093/ejendo/lvae147

Verify or expand the search:

Other trials of Secretin

Trials testing the same drug.

NCT03686618 — Secretin for Acute Pancreatitis · Phase 2 · unknown
NCT02869893 — MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics · NA · completed

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Steno Diabetes Center Copenhagen trials

Trials by the same sponsor.

NCT07485075 — Digital Support for Reducing Salt Intake Among Patients With Diabetic Kidney Disease: Protocol for a Controlled Clinical · NA · recruiting
NCT07427251 — The Postprandial Hypo-Avoid Study · Phase 4 · not yet recruiting
NCT06954090 — Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study · Phase 4 · enrolling by invitation
NCT06832059 — Precision Nutrition Versus Standard Dietary Care: Continuous Glucose Monitoring as a Tool for Guided Nutrition Care in T · NA · recruiting
NCT07377266 — The Impact of Changing to a New Child- and Family-centered Outpatient Diabetes Clinic Focusing on Early Involvement of t · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04613700 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Steno Diabetes Center Copenhagen
Last refreshed: 5 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04613700.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing